Mylan Inc. Tries to Get Its Hands on Ranbaxy Laboratories' Rights Over Novartis AG's Diovan
Mylan Inc. Tries to Get Its Hands on Ranbaxy Laboratories ' Rights Over Novartis AG 's Diovan The Swiss drug maker Novartis had been bracing all year for the day in late September when Diovan, its top-selling blood pressure drug, would lose patent protection and a cheaper generic version would become available.
Join the discussion below, or Read more at BioSpace.
#1 Dec 8, 2012
We still do not know why Ranbaxy's Diovan application has not been approved. Can anyone speculate why this is so?
Ranbaxy used to be a great company under parminder singh and Brar. company was destroyed by mavinder.
I would sell its stock until the Japaese straighten it out. will take time -- don't expect immediate results once a culture is destroyed.
Also, the Indian financial community is not putting pressure on the company does not understand the business -- they will take time to grasp the impact of the lipitor generic withdrawal in the us and the complete loss of that part of the us business.
Add your comments below
|Ranbaxy announces USFDA approval of CIP-Isotret... (Aug '12)||Sep '13||De Croft||9|
|Company Completely Halts Generic Lipitor Produc... (Dec '12)||Dec '12||Pharmaman||1|
Find what you want!
Search Ranbaxy Laboratories Forum Now
Copyright © 2017 Topix LLC